Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bangkok Genomics Innovation Public Company Limited (BKGI.BK)
Bangkok, TH
Bangkok Genomics Innovation Public Company Limited, trading as BKGI.BK, is a Thailand-based enterprise delivering a diverse array of clinical and genomic services. Their core genetic offerings include the NIFTY brand for non-invasive prenatal testing, screening for fetal chromosomal abnormalities, and the VISTA brand, which provides genetic disease carrier screening for applications such as pre-embryo implantation, general carrier status, and the detection of gene anomalies linked to thalassemia anemia. Additionally, they offer HPV DNA testing, colon cancer screening under the COLOTECH brand, and personalized genetic analyses through the DNALL brand. Beyond genetic diagnostics, the company provides comprehensive testing for infectious diseases, including real-time PCR, antigen, serology, and neutralizing antibody assays for COVID-19, alongside real-time PCR testing for the monkeypox virus. Their technology solutions segment covers advanced services like DNA and RNA base sequencing, as well as metabolism and protein omics tests. The company also acts as a distributor for essential medical supplies, such as PCR COVID-19 test kits, personal protective equipment (PPE), and vital transport media. BKGI's broader service portfolio encompasses health analytics, medical care, and the development of biotechnology products. They also offer cell advanced therapy medicinal products and provide consulting services for small businesses. Furthermore, the company operates an education center, engages in research activities, and is involved in the retail sale of pharmaceutical products. Remarkably, their operations extend into other sectors, including the provision of heavy machinery such like hydraulic excavators, tractors, wheel-loaded air compressors, and their spare parts, in addition to real estate development. Founded in 2017, Bangkok Genomics Innovation Public Company Limited is headquartered in Bangkok, Thailand.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.55% | +7.74% | +37.12% | +28.37% | +35.07% | +41.41% | +7.10% | +11.04% | +11.04% | +11.04% | +11.04% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2025-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 1 | 0 |
-
Revenue growth Medical - Diagnostics & Research: +7.9%+12.4% ★ Q1'26: +93.8% (vs Q1'25)
-
EPS growth Medical - Diagnostics & Research: +30.8%-14.6% Q1'26: +285.9% (vs Q1'25)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%-32.2% Q1'26: +20.5% (vs Q1'25)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+11.2% ★ Q1'26: +23.0% (vs Q1'25)
-
ROIC Medical - Diagnostics & Research: +5.2%+10.9% ★ Q1'26: +33.6% (vs Q1'25)
-
Share dilution Medical - Diagnostics & Research: 0.0%+5.8% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×0.60× ★ Q1'26: 0.12× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|
| Revenue |
245.39M
est: 241.00M (+1.8%)
|
337.59M
est: 351.00M (-3.8%)
|
379.51M
est: 370.00M (+2.6%)
|
400.00M
400.00M – 400.00M
+8.1% YoY
|
433.00M
433.00M – 433.00M
+8.3% YoY
|
| EBITDA |
49.55M
est: 57.12M (-13.3%)
|
70.17M
est: 83.61M (-16.1%)
|
63.95M
est: 88.14M (-27.5%)
|
95.29M
95.29M – 95.29M
+8.1% YoY
|
103.15M
103.15M – 103.15M
+8.2% YoY
|
| EBIT |
33.58M
est: 45.34M (-25.9%)
|
52.38M
est: 66.44M (-21.2%)
|
42.40M
est: 70.04M (-39.5%)
|
75.72M
75.72M – 75.72M
+8.1% YoY
|
81.97M
81.97M – 81.97M
+8.3% YoY
|
| Net Income |
32.14M
est: 35.92M (-10.5%)
|
50.17M
est: 54.00M (-7.1%)
|
45.35M
est: 54.00M (-16.0%)
|
60.00M
60.00M – 60.00M
+11.1% YoY
|
66.00M
66.00M – 66.00M
+10.0% YoY
|
| SGA |
85.22M
est: 60.41M (+41.1%)
|
94.50M
est: 96.53M (-2.1%)
|
107.64M
est: 101.75M (+5.8%)
|
110.00M
110.00M – 110.00M
+8.1% YoY
|
119.08M
119.08M – 119.08M
+8.2% YoY
|
| EPS |
0.05
est: 0.06 (-15.4%)
|
0.09
est: 0.09 (-1.7%)
|
0.08
est: 0.09 (-16.0%)
|
0.10
0.10 – 0.10
+11.1% YoY
|
0.11
0.11 – 0.11
+10.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-21 | A | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-20 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-19 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-18 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-15 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-14 | A- | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 2/5 | 4/5 |
| 2026-05-13 | A | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-12 | A | 4/5 | 3/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-11 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-08 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-05 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-30 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-29 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-28 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-27 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-24 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-23 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A- | 4/5 | 3/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Benjarat Chaowongpanich | company secretary | — | female |
| Kittikun Rod Rang Nok | Chief Financial Officer | — | male |
| Porntep Tanyut | Chief Operating Officer | — | male |
| Puttarawicha Mhankid | company secretary | — | female |
| Saowalak Dansakul | Chief Executive Officer & Director | — | — |
| Xiaohan Wang | Deputy Chief Executive Officer, Acting Chief Business Officer & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BKGI.BK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
